Composite dissolvable microneedle patch for therapy of oral mucosal diseases
Source abstract
Abstract
A composite microneedle patch (MN patch) is developed for oral transmucosal administration. To improve the oral transmucosal drug delivery efficiency, the composite MN patch is designed to consist of an array of 100 dissolvable microneedles (MNs) with drug-loaded tips and a backing layer. The MNs are composed of two parts, the hyaluronic acid (HA) tip part and the polyvinylpyrrolidone (PVP) base part. Due to the small size and sufficient mechanical strength, the HA-PVP MNs can painlessly penetrate the oral mucosa barrier and deliver drugs directly to the basal layer or submucosa. Betamethasone sodium phosphate (BSP), as the model drug, is concentrated in the HA tip parts to avoid the drug waste caused by mucosa elasticity. Considering the special moist environment and saliva flow in the mouth, a double-layer backing layer composed of a poly(vinyl alcohol) (PVA) adhesive layer and an ethyl cellulose (EC) waterproof layer is designed and constructed, which could reduce the saliva flow effects. The in vitro and in vivo results demonstrate that the MN patch could achieve rapid and efficient BSP release in oral mucosa due to the rapid dissolution of HA. The proposed MN patch provides a novel strategy for the therapy of oral mucosal diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Salivary Gland Disorders and Functions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Local drug delivery for oral mucosal diseases: challenges and opportunities10.1111/j.1601-0825.2011.01793.x ↗
2. Oral local drug delivery and new perspectives in oral drug formulation10.1016/j.oooo.2012.02.016 ↗
3. Nonneoplastic diseases and disorders of the oral mucosa: a contemporary overview
4. Quality of life in patients with Oral potentially malignant disorders: a systematic review10.1016/j.oooo.2015.01.025 ↗
5. Impact of oral mucosa lesions on the quality of life related to oral health. An etiopathogenic study10.4317/medoral.20866 ↗
6. Impact of oral potentially malignant disorders on quality of life10.1111/jop.12620 ↗
7. Oral mucosal disease: recurrent aphthous stomatitis10.1016/j.bjoms.2007.07.201 ↗
8. The management of mucous membrane pemphigoid and pemphigus10.1111/j.1529-8019.2010.01323.x ↗
9. Recurrent aphthous ulceration: an epidemiological study of etiological factors, treatment and differential diagnosis10.1590/abd1806-4841.20186228 ↗
10. Interventions for the management of oral lichen planus: a review of the conventional and novel therapies10.1111/odi.12634 ↗
11. Interventions for treating oral lichen planus: corticosteroid therapies
12. Treatment trends in oral lichen planus and oral lichenoid lesions (review)10.3892/etm.2020.9328 ↗
13. Microneedle technology for immunisation: perception, acceptability and suitability for paediatric use10.1016/j.vaccine.2015.12.002 ↗
14. Transdermal drug delivery10.1038/nbt.1504 ↗
15. Advances in oral transmucosal drug delivery10.1016/j.jconrel.2011.01.027 ↗
16. Microneedles for transdermal biosensing: current picture and future direction10.1002/adhm.201500450 ↗
17. Magneto-responsive microneedle robots for intestinal macromolecule delivery
18. Polymeric microneedles for controlled transdermal drug delivery10.1016/j.jconrel.2019.10.022 ↗
19. Advances in antimicrobial microneedle patches for combating infections10.1002/adma.202002129 ↗
20. Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity10.1007/s11095-014-1335-1 ↗
21. Microneedle-mediated vaccine delivery to the oral mucosa10.1002/adhm.201801180 ↗
22. A microneedle platform for buccal macromolecule delivery10.1126/sciadv.abe2620 ↗
23. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system10.1016/j.vaccine.2007.10.020 ↗
24. Versatile ice microneedles for transdermal delivery of diverse actives
25. Influence of salivary washout on drug delivery to the oral cavity using coated microneedles: an in vitro evaluation10.1016/j.ejps.2016.08.023 ↗
26. Microneedles and nanopatches-based delivery devices in dentistry10.15190/d.2020.13 ↗
27. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety10.3109/10717541003667798 ↗
28. Lack of pain associated with microfabricated microneedles10.1213/00000539-200102000-00041 ↗
29. A crossover clinical study to evaluate pain intensity from microneedle insertion in different parts of the oral cavity10.1016/j.ijpharm.2020.120050 ↗
30. Microneedle patches for vaccination in developing countries10.1016/j.jconrel.2015.11.019 ↗
31. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial10.1016/S0140-6736(17)30575-5 ↗
32. Drug coated microneedles for minimally-invasive treatment of oral carcinomas: development and in vitro evaluation10.1007/s10544-015-9944-y ↗
33. Microneedles-based transdermal drug delivery dystems: a review10.1166/jbn.2017.2474 ↗
34. Dissolving microneedle dystems for the oral mucosal delivery of triamcinolone acetonide to treat aphthous stomatitis10.1007/s13233-019-7031-6 ↗
35. Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin10.1016/j.actbio.2015.06.021 ↗
36. Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: a randomized comparative study10.1016/j.jaad.2007.11.022 ↗
37. Efficacy of intralesional betamethasone for erosive Oral lichen planus and evaluation of recurrence: a randomized, controlled trial, Oral surg10.1016/j.oooo.2013.07.023 ↗
38. Recurrent aphthous stomatitis: a review10.1111/j.1600-0714.2012.01134.x ↗
39. A proposed model membrane and test method for microneedle insertion studies10.1016/j.ijpharm.2014.05.042 ↗
40. Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery10.1038/s41467-018-06981-w ↗
41. GPR39 overexpression in OSCC promotes YAP-sustained malignant progression10.1177/0022034520915877 ↗
42. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force10.1016/j.jbiomech.2003.12.010 ↗
43. Hyaluronic acid increases tendon derived cell viability and proliferation in vitro: comparative study of two different hyaluronic acid preparations by molecular weight10.32098/mltj.02.2017.02 ↗
44. Oral transmucosal drug delivery for pediatric use10.1016/j.addr.2013.08.011 ↗